General Information of Drug (ID: DMVOGT4)

Drug Name
PREMETREXED Drug Info
Synonyms [3H]pemetrexed
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
394493
TTD Drug ID
DMVOGT4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Investigative Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [4]
Folic Acid DMEMBJC Colorectal carcinoma Approved [4]
[3H]N5-methylfolate DM0THB9 Discovery agent N.A. Investigative [4]
[3H]folinic acid DME0XHN Discovery agent N.A. Investigative [4]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [5]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [6]
Pemetrexed DMMX2E6 Central nervous system lymphoma 2B33.5 Approved [7]
Trifluridine DMG2YBD Herpetic keratitis 1F00.10 Approved [8]
Capecitabine DMTS85L Adenocarcinoma 2D40 Approved [9]
Raltitrexed DMT9K8G Rectal adenocarcinoma 2B92 Approved [10]
Floxuridine DM04LR2 Colorectal cancer 2B91.Z Approved [11]
Flucytosine DM13VTW Cryptococcal meningitis Approved [12]
Nolatrexed DMOF0CA Solid tumour/cancer 2A00-2F9Z Phase 3 [13]
Plevitrexed (R)-isomer DMTL39C Gastric adenocarcinoma 2B72 Phase 2 [14]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Proguanil DMBL79I Malaria 1F40-1F45 Approved [15]
Meprobamate DMHM93Y Anxiety Approved [16]
Pralatrexate DMAO80I Breast cancer 2C60-2C65 Approved [17]
Ustekinumab DMHTYK3 Plaque psoriasis EA90.0 Approved [18]
Trimetrexate DMDEA85 Toxoplasmosis 1F57 Approved [19]
MCB-3837 DM0R4Z5 Malaria 1F40-1F45 Approved [16]
Chlorproguanil DM1IFGT Malaria 1F40-1F45 Approved [16]
LY333531 DMGMC8H Solid tumour/cancer 2A00-2F9Z Phase 2 [20]
Metoprine DM5GQD7 Advanced cancer 2A00-2F9Z Phase 2 [21]
Aminopterin DMQ9RBV leukaemia 2A60-2B33 Withdrawn from market [6]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Candida Thymidylate synthase (Candi TMP1) TTU6BFZ TYSY_CANAL Inhibitor [2]
Polypeptide deformylase (PDF) TT9SL3Q DEFM_HUMAN Inhibitor [3]
Proton-coupled folate transporter (SLC46A1) TTY8Z2E PCFT_HUMAN Modulator [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6688).
2 Dual inhibitors of thymidylate synthase and dihydrofolate reductase as antitumor agents: design, synthesis, and biological evaluation of classical ... J Med Chem. 2006 Feb 9;49(3):1055-65.
3 Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines. J Med Chem. 2001 Jun 7;44(12):1993-2003.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1213).
5 The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol. 2004 Apr;53(4):296-304.
6 Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.
7 Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S35-40.
8 Trifluorothymidine induces cell death independently of p53. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):699-703.
9 UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36.
10 DNA damage and homologous recombination signaling induced by thymidylate deprivation. Biochem Pharmacol. 2008 Oct 15;76(8):987-96.
11 Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol. 1999 Aug;127(8):1777-86.
12 Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9.
13 A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration. Br J Cancer. 1999 Feb;79(5-6):915-20.
14 Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors. Biochemistry. 2007 Mar 13;46(10):2823-30.
15 Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10931-6.
16 The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
17 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
18 Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob Agents Chemother. 2002 Nov;46(11):3362-9.
19 Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase. Antimicrob Agents Chemother. 2000 Nov;44(11):3092-6.
20 Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J Mol Biol. 2000 Jan 14;295(2):307-23.
21 Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.